NSE: IKS

Business news, market intelligence, and global industry analysis.

The Latest

Akeso moves bispecific ADCs into Phase II as IO 2.0 combination strategy enters mid-stage development

Representative image of an online fashion retail and stock market rebound theme illustrating the ASOS Plc H1 FY26 update, as EBITDA rose about 50%, full-year guidance was maintained, and ASOS shares jumped 16% on turnaround optimism.

ASOS (LSE: ASC) H1 FY26 update: EBITDA surges 50%, guidance held as shares jump 16%

Representative image of a graphite mine and battery materials processing facility linked to Syrah Resources’ trading halt, lender funding package talks, and potential equity raise tied to Balama and Vidalia operations.

Syrah Resources (ASX: SYR) enters trading halt to finalise lender funding package and potential equity raise

BPCL and Sembcorp JV NeuEN bags India’s lowest green hydrogen tariff at Rs 279/kg in 10KTPA Numaligarh Refinery contract

IKS Health (NSE: IKS) and Certilytics expand agentic AI partnership to automate prior authorisation and close the payer-provider gap

IKS Health and Certilytics expand agentic AI to automate 70% of US prior authorisation workflows. Read what it means for payers, providers, and NSE: IKS.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 25, 2026